Pharmacokinetics of acetazolamide after intravenous and oral administration in horses

American Journal of Veterinary Research

Volumn 61, Issue 8, 2000, Pages 965-968

  Alberts, Michael K ^a,b   Clarke, Cyril R ^a   MacAllister, Charles G ^a   Homer, Lynne M ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b Cedar Creek Equine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; NONHUMAN; ANIMAL; ANIMAL DISEASE; BIOAVAILABILITY; BLOOD; CROSSOVER PROCEDURE; FEMALE; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; REGRESSION ANALYSIS;

ACETAZOLAMIDE; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBONIC ANHYDRASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HORSES; INJECTIONS, INTRAVENOUS; LEAST-SQUARES ANALYSIS; MALE;

EID: 0033624302     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2000.61.965     Document Type: Article

References (33)

1. Leaf AL, Schwartz WB, Relman AS. Oral administration of a potent carbonic anhydrase inhibitor ("Diamox") I. Changes in electrolyte and acid-base balance. N Engl J Med 1954;250: 759-763.
2. Spaeth GL. Potassium, acetazolamide, and intraocular pressure. Arch Ophthalmol 1967;78:578-582.
3. Trudell RG, Kaiser KK, Griggs RC. Acetazolamide responsive myotonia congenita. Neurology 1987;37:488-491.
4. Hoskins B. Studies on the mechanism of action of acetazolamide in the prophylaxis of hyperkalemic periodic paralysis. Life Sci 1977;20:343-349.
5. Reiss WG, Oles KS. Acetazolamide in the treatment of seizures. Ann Pharmacother 1996;30:514-519.
6. Larson EB, Roach RC, Schoene RB, et al. Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA 1982;248:328-332.
7. Regnier A, Toutain PL. Ocular pharmacology and therapeutic modalities. In: Gelatt KN, ed. Veterinary ophthalmology. 2nd ed. Philadelphia: Lea & Febiger, 1991;162-194.
8. Gouge HE, Shor AL, Johnson WP. Control of udder edema in dairy cows: clinical evaluation of acetazolamide sodium. Vet Med (Praha) 1959;54:343-345.
9. Vestweber JGE, Al-Ani FK, Johnson DE. Udder edema in cattle: effects of diuretics (furosemide, hydrochlorothiazide, acetazolamide, and 50% dextrose) on serum and urine electrolytes. Am J Vet Res 1989;50:1323-1328.
10. Cox JH. An episodic weakness in four horses associated with intermittent serum hyperkalemia and the similarity of the disease to hyperkalemic periodic paralysis in man. Proc Am Assoc Equine Pract 1985;31:383-391.
11. Spier SJ, Carlson GP, Holliday TA, et al. Hyperkalemic periodic paralysis in horses. J Am Vet Med Assoc 1990;197:1009-1016.
12. Cox JH, DeBowes RM. Episodic weakness caused by hyperkalemic periodic paralysis in horses. Compend Contin Educ Pract Vet 1990;12:83-88.
13. Beech J, Lindborg S. Prophylactic efficacy of phenytoin, acetazolamide and hydrochlorothiazide in horses with hyperkalaemic periodic paralysis. Res Vet Sci 1995;59:95-101.
14. Guglick MA, MacAllister CG, Breazile JE. Laryngospasm, dysphagia, and emaciation associated with hyperkalemic periodic paralysis in a horse. J Am Vet Med Assoc 1996;209:115-117.
15. Carr EA, Spier SJ, Kortz GD, et al. Laryngeal and pharyngeal dysfunction in horses homozygous for hyperkalemic periodic paralysis. J Am Vet Med Assoc 1996;209:798-803.
16. Hossie RD, Mousseau N, Sved S, et al. Quantitation of acetazolamide in plasma by high performance liquid chromatography. J Pharm Sci 1980;69:348-349.
17. Hartley R, Lucock M, Becker M, et al. Solid-phase extraction of acetazolamide from biological fluids and subsequent analysis by high-performance liquid chromatography. J Chromatogr 1986;377:295-305.
18. 2 uptake. J Appl Physiol 1990;68:617-626.
19. Brown RD, Manno JE. ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 1978;67:1687-1691.
20. Bourne DW. BOOMER, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis. Comput Methods Programs Biomed 1989;29:191-195.
21. Baggot JD. Principles of pharmacokinetics. In: Principles of drug disposition in domestic animals. The basis of veterinary clinical pharmacology. Philadelphia: WB Saunders Co, 1977;144-189.
22. + channel mutation alters molecular transitions between the open and inactivated states. J Physiol 1996;497:349-364.
23. Jackson EK. Diuretics. In: Hardman JG, Limbird LE, Molinoff PB, et al. eds. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed, New York: McGraw-Hill Book Co, 1996; 691-695.
24. Haskins SC, Munger RJ, Helphrey MG, et al. Effect of acetazolamide on blood acid-base and electrolyte values in dogs. J Am Vet Med Assoc 1981;179:792-796.
25. Heller I, Halevy J, Cohen S, et al. Significant metabolic acidosis induced by acetazolamide. Not a rare complication. Arch Intern Med 1985;145:1815-1817.
26. Martinez MN. Use of pharmacokinetics in veterinary medicine. Article II: volume, clearance, and half-life. J Am Vet Med Assoc 1998;213:1122-1127.
27. Yakatan GJ, Frome EL, Leonard RG, et al. Bioavailability of acetazolamide tablets. J Pharm Sci 1978;67:252-256.
28. Friedland BR, Mallonee J, Anderson DR. Short-term dose response characteristics of acetazolamide in man. Arch Ophthalmol 1977;95:1809-1812.
29. Ritschel WA, Paulos C, Arancibia A, et al. Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude. J Clin Pharmacol 1998;38:533-539.
30. Maren TH, Mayer E, Wadsworth BC. Carbonic anhydrase inhibilion I: the pharmacology of Diamox 2-acetylamino-1,3,4-thiadiazole-5-sulfonamide. Bull Johns Hopkins Hosp 1954;95:199-243.
31. Ellis PP, Price PK, Kelmenson R, et al. Effectiveness of generic acetazolamide. Arch Ophthalmol 1982;100:1920-1922.
32. Celebisoy N, Colakoglu Z, Akbaba Y, et al. Continuous muscle fibre activity: a case treated with acetazolamide. J Neurol Neurosurg Psychiatry 1998;64:256-258.
33. Vroom FW, Jarrell MA, Maren TH. Acetazolamide treatment of hypokalemic periodic paralysis. Probable mechanism of action. Arch Neurol 1975;32:385-392.